Key statistics dashboard for Solid Biosciences Inc. (SLDB). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD.
Stock Data
| Price | $8.72 |
| Market Cap | $858M |
| Enterprise Value | $719.2M |
| Beta | 2.58 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -4.40 |
| Price / Book | 3.23 |
| P/S | 0.00 |
| EV/EBITDA | -3.51 |
| EV/Sales | 0.00 |
| EV/FCF | -3.83 |
| P/FCF | -4.41 |
| Earnings Yield | -16.53% |
| FCF Yield | -21.88% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -72.28% |
| Return on Assets | -49.24% |
| Return on Invested Capital | -53.81% |
| Return on Capital Employed | -54.12% |
Financial Health
| Current Ratio | 13.82 |
| Quick Ratio | 13.82 |
| Cash Ratio | 5.58 |
| Debt / Equity | 0.05 |
| Debt / Assets | 4.79% |
| Net Debt / EBITDA | 0.68 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 2.60 |
| Cash per share | 2.63 |
| FCF per share | -1.31 |
| Tangible Book Value per share | 2.60 |
| Dividend per share | 0.00 |
Related companies: ANNX · AURA · AUTL · BNTC · DSGN · LBRX · NMRA
Explore sector: Healthcare · Biotechnology
More sections of SLDB: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks